Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
CompletedPhase 3NCT03867201
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
Study details
- Official title
- A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients
- Conditions
- Interventions
- Sponsor
- Novartis Pharmaceuticals
- Organization
- Novartis
- Start date
- 2019-08-26
- Primary completion
- 2021-08-11
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- China, India, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
- Total sites listed
- 63
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
key inclusion Criteria: 1. History of at least 5 attacks of migraine 2. ≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period 3. \>=80% diary compliance during the baseline period Key exclusion Criteria: 1. Older than 50 years of age at migraine onset 2. History of cluster or hemiplegic headache 3. Evidence of seizure or major psychiatric disorder 4. Cardiac or active hepatic disease 5. Pregnant or nursing
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03867201